ABCA1 inducer 2 is a non-lipotropic ABCA1 inducer. ABCA1 inducer 2 upregulates the expression of ABCA1 by targeting the LXR pathway. ABCA1 inducer 2 can reduce ox-LDL-induced lipid accumulation and thus inhibit foam cell formation. ABCA1 inducer 2 has anti-atherosclerotic potential [1].
In Vitro, ABCA1 inducer 2 (Compound 3) (0.01-10 μM, 24 h) has a strong ability to activate the ABCA1 promoter in Hela cells[1]. ABCA1 inducer 2 (0.01-10 μM, 18 h) effectively induces the expression of ABCA1 mRNA in RAW 264.7 cells in a dose-dependent manner, with the maximum increase at 10 μM being 3.94-fold of that in the control group[1]. ABCA1 inducer 2 (0.01-10 μM, 12-48 h) upregulates ABCA1 protein expression in RAW 264.7 cells and Hela cells by acting on the LXR pathway[1]. ABCA1 inducer 2 (10 μM, 24 h) can effectively reduce ox-LDL-induced intracellular lipid accumulation and inhibit the formation of foam cells in RAW 264.7 cells[1]. ABCA1 inducer 2 (10 μM, 48 h) induces limited lipid and triglyceride accumulation in HepG2 cells, reduces adverse effects associated with hypertriglyceridemia and hepatic lipogenesis[1]. ABCA1 inducer 2 (0.01-10 μM, 24 h) has no significant toxicity to Hela, RAW264.7 and HepG2 cells at a concentration of 10 μM[1].
References:
[1]. Yang C, et al. Synthesis and evaluation of 5, 6-dihydro-8H-isoquinolino[1, 2-b]quinazolin-8-one derivatives as novel non-lipogenic ABCA1 up-regulators with inhibitory effects on macrophage-derived foam cell formation. J Enzyme Inhib Med Chem. 2025 Dec;40(1):2470310.
In Vitro, ABCA1 inducer 2 (Compound 3) (0.01-10 μM, 24 h) has a strong ability to activate the ABCA1 promoter in Hela cells[1]. ABCA1 inducer 2 (0.01-10 μM, 18 h) effectively induces the expression of ABCA1 mRNA in RAW 264.7 cells in a dose-dependent manner, with the maximum increase at 10 μM being 3.94-fold of that in the control group[1]. ABCA1 inducer 2 (0.01-10 μM, 12-48 h) upregulates ABCA1 protein expression in RAW 264.7 cells and Hela cells by acting on the LXR pathway[1]. ABCA1 inducer 2 (10 μM, 24 h) can effectively reduce ox-LDL-induced intracellular lipid accumulation and inhibit the formation of foam cells in RAW 264.7 cells[1]. ABCA1 inducer 2 (10 μM, 48 h) induces limited lipid and triglyceride accumulation in HepG2 cells, reduces adverse effects associated with hypertriglyceridemia and hepatic lipogenesis[1]. ABCA1 inducer 2 (0.01-10 μM, 24 h) has no significant toxicity to Hela, RAW264.7 and HepG2 cells at a concentration of 10 μM[1].
References:
[1]. Yang C, et al. Synthesis and evaluation of 5, 6-dihydro-8H-isoquinolino[1, 2-b]quinazolin-8-one derivatives as novel non-lipogenic ABCA1 up-regulators with inhibitory effects on macrophage-derived foam cell formation. J Enzyme Inhib Med Chem. 2025 Dec;40(1):2470310.